Bio-Techne (TECH) FY2025 10-K Annual Report
Bio-Techne (TECH) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Aug 22, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Bio-Techne FY2025 10-K Analysis
Business Overview
- • Core business model: Life sciences reagents, instruments, and services for research and clinical diagnostics
- • No new products, services, or segments introduced or emphasized this year according to filing text
- • No reported strategic shift or changed competitive positioning vs prior year
- • Filing emphasizes extensive incorporation by reference to prior filings for governance, compensation, and legal matters, maintaining existing corporate structures
- • Noteworthy: Filing contains no standalone 'Business' description content; relies entirely on cross-references and exhibits
Management Discussion & Analysis
- • Revenue $1.22B in FY2025, up 5% YoY; Protein Sciences sales $870.2M (+5%), Diagnostics and Spatial Biology $346.3M (+6%)
- • Gross margin declined to 64.8% in FY2025 vs 66.4% in FY2024; Protein Sciences margin 75.6% vs 75.7%, Diagnostics 57.3% vs 58.7%
- • Best performing segment Diagnostics and Spatial Biology with 6% sales growth; worst Protein Sciences with 5% sales growth but margin pressure
- • Operating expenses rose 26% to $588.5M in FY2025; net earnings down 56% to $98.5M driven by non-recurring arbitration loss and impairments
- • Operating cash flow $287.6M in FY2025; capital expenditures $31M; share repurchases $275.7M; dividends $50.4M
- • Management expects to meet cash needs through operations and credit facility; plans $42M capex in FY2026; risk from arbitration costs and Wilson Wolf acquisition milestone contingent payments (~$1B forecasted)
Risk Factors
- • Cybersecurity risk due to potential breaches despite industry-standard defenses, reliance on third-party software and service providers increasing vulnerability
- • Cyber insurance coverage may be insufficient to cover claims arising from security breaches or cyberattacks
- • No specific regulatory, geopolitical, supply chain, competitive, or financial risks detailed in provided text
Bio-Techne FY2025 Key Financial MetricsXBRL
Revenue
$1.2B
▲ +5.2% YoY
Net Income
$73M
▼ -56.3% YoY
Gross Margin
64.8%
▼ -161bp YoY
Operating Margin
8.4%
▼ -945bp YoY
Net Margin
6.0%
▼ -849bp YoY
ROE
3.8%
▼ -430bp YoY
Total Assets
$2.6B
▼ -5.4% YoY
EPS (Diluted)
$0.46
▼ -56.2% YoY
Operating Cash Flow
$288M
▼ -3.8% YoY
Source: XBRL data from Bio-Techne FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Bio-Techne
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.